Skip to content

Aspira Women's Health Inc.

AWHL

CIK 0000926617 · In Vitro & In Vivo Diagnostic Substances · OTC

  • VERMILLION, INC. (until 2020-06-10)
  • CIPHERGEN BIOSYSTEMS INC (until 2007-08-17)
← back to feed
Revenue (TTM)
$8.96M
+0.4% YoY Q1 May 2026
Net Income (TTM)
−$8.74M
+2.4% YoY Q1 May 2026
EPS Diluted (TTM)
−$0.34
+60.2% YoY Q1 May 2026
Gross Margin
62.0%
Q1 May 2026
Operating Margin
-98.6%
Q1 May 2026
Net Margin
-97.5%
Q1 May 2026
Free Cash Flow (TTM)
−$4.72M
Q1 May 2026
Cash
$1.34M
Q1 May 2026
Total Debt
$2.85M
Q1 May 2026
Shares Outstanding
43.5M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings